{"gene":"CBFB","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1995,"finding":"CBF-C (NF-YC) is required together with CBF-A and CBF-B to form a CBF-DNA complex on CCAAT motifs; CBF-A and CBF-C interact with each other to form a heterodimer, and CBF-B associates with the CBF-A–CBF-C complex but not with either subunit individually.","method":"Recombinant protein reconstitution, EMSA, immunoprecipitation with purified subunits expressed in E. coli","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified recombinant proteins, EMSA, and immunoprecipitation; results replicated across multiple binding and co-complex experiments in a single rigorous study","pmids":["7878029"],"is_preprint":false},{"year":1996,"finding":"CBF-B interacts simultaneously with both CBF-A and CBF-C subunits to form a heterotrimeric CBF molecule; the evolutionarily conserved histone-fold motif segment of CBF-C is necessary for CBF-DNA complex formation; CBF-A and CBF-C interact via histone-fold motifs to form a heterodimer that generates a hybrid surface for CBF-B interaction.","method":"Cross-linking, immunoprecipitation, mutational analysis of CBF-C, in vitro EMSA, yeast two-hybrid","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (crosslinking, IP, mutagenesis, yeast two-hybrid, in vitro assay) in one rigorous study defining interaction domains","pmids":["8754798"],"is_preprint":false},{"year":1996,"finding":"CBF transcriptional activation is mediated by two distinct activation domains: one in CBF-B (N-terminal residues 1–224) and one in CBF-C (C-terminal residues 114–309); the two domains act additively in an in vitro transcription assay.","method":"In vitro transcription reconstitution with purified recombinant CBF subunits and deletion mutants, nuclear extract depletion/add-back assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with deletion mutants clearly defining activation domains; single lab but multiple constructs tested","pmids":["8662945"],"is_preprint":false},{"year":1996,"finding":"The CBFB-MYH11 fusion oncogene, generated by inv(16), acts as a dominant negative inhibitor of normal CBFB/RUNX1 function; heterozygous knock-in of Cbfb-MYH11 in mice blocks definitive hematopoiesis, phenocopying homozygous deletion of Cbfb or Cbfa2 (AML1/RUNX1).","method":"Knock-in mouse model (homologous recombination ES cells), chimeric mouse analysis, embryo phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knock-in with defined hematopoietic phenotype, epistasis with Cbfb and Cbfa2 null alleles; replicated in subsequent studies","pmids":["8929537"],"is_preprint":false},{"year":1996,"finding":"The CBFB-MYH11 fusion protein (CBFβ-SMMHC) is expressed as a ~70–95 kDa protein in inv(16) AML patient nuclei and forms a very high molecular weight protein-DNA complex in electrophoretic mobility shift assays; the protein is organized into novel structures within cell nuclei.","method":"Western blot with anti-CBFB and anti-MYH11 antisera, EMSA with patient nuclear extracts, immunofluorescence staining","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunofluorescence and EMSA in primary patient cells; single lab, multiple methods","pmids":["8818654"],"is_preprint":false},{"year":2000,"finding":"Zebrafish cbfb protein binds to human CBFα2 (RUNX1) and enhances its DNA binding activity; cbfb is expressed in early hematopoietic progenitors in the intermediate cell mass, and its expression pattern resembles that of scl in hematopoietic mutants.","method":"Biochemical binding assay (recombinant protein), EMSA, in situ hybridization during zebrafish development, analysis in hematopoietic mutant zebrafish","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA-binding enhancement shown biochemically; in vivo expression in genetic mutants; single lab, two orthogonal methods","pmids":["11110689"],"is_preprint":false},{"year":2001,"finding":"Expression of CBFB-MYH11 leads to sequestration of CBFα2 (RUNX1) in the cytoplasm, inhibits CBF-mediated transactivation, slows cell cycle progression, delays apoptotic response to DNA-damaging agents, and protects CBFα2 from degradation.","method":"In vitro cell transfection studies, reporter assays (review summarizing published experiments)","journal":"Current opinion in hematology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — review summarizing multiple cell-based experiments from prior publications; mechanisms individually supported by prior experimental work","pmids":["11561156"],"is_preprint":false},{"year":2002,"finding":"Cbfb is expressed in hematopoietic stem cells and progenitors during midgestation and in adult myeloid and lymphoid cells but not during terminal erythropoiesis; Cbfb-MYH11 blocks embryonic hematopoiesis at the stem-progenitor cell level.","method":"Cbfb-GFP knock-in mouse model, flow cytometry of hematopoietic populations, comparison with Cbfb-MYH11 knock-in embryos","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in reporter mouse with flow cytometry defining cell-specific expression and functional block; replicated in multiple knock-in models","pmids":["12239155"],"is_preprint":false},{"year":2003,"finding":"Cbfb is required for the functions of both Runx1 and Runx2 in hematopoiesis and skeletal development; Runx2/Cbfb heterodimers play essential roles in osteoblast differentiation and chondrocyte maturation.","method":"Cbfb knockout mouse rescue experiments, genetic analysis of skeletal and hematopoietic phenotypes","journal":"Journal of bone and mineral metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined skeletal/hematopoietic phenotype; single lab review summarizing prior experiments","pmids":["12811622"],"is_preprint":false},{"year":2005,"finding":"CBFβ-SMMHC (CBFB-MYH11 fusion protein) suppresses CEBPA protein expression and binding activity post-translationally by inducing calreticulin, an inhibitor of CEBPA translation; CEBPA mRNA levels are unchanged, but protein and binding activity are reduced; siRNA knockdown of calreticulin restores CEBPA protein levels.","method":"Conditional expression of CBFB-SMMHC in U937 cells, Western blot, EMSA, siRNA knockdown, mRNA quantification (qRT-PCR), patient sample analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (conditional expression, siRNA rescue, EMSA, patient samples) in a single study establishing a novel translational mechanism","pmids":["15855281"],"is_preprint":false},{"year":2007,"finding":"Cbfb enhances osteogenic differentiation of mesenchymal stem cells by stabilizing Cbfa-1 (RUNX2) through suppression of ubiquitination-mediated proteasomal degradation; Cbfb alone does not trigger osteogenesis.","method":"Recombinant adenovirus overexpression of Cbfb and Cbfa-1 in mouse C3H10T1/2 cells and human BMSCs, Western blot, ubiquitination assay, alkaline phosphatase assay","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ubiquitination assay combined with protein stability experiments; single lab with two orthogonal methods","pmids":["17379770"],"is_preprint":false},{"year":2009,"finding":"CBFB-MYH11 causes Cbfb/Runx1 repression-independent hematopoietic defects, including sustained expression of Gata2, Il1rl1, and Csf2rb in primitive hematopoiesis and accumulation of abnormal Csf2rb-expressing progenitors — a phenotype not found in Cbfb or Runx1 knockout mice — demonstrating that CBFβ-SMMHC has leukemogenic activities independent of dominant RUNX1 repression.","method":"Cbfb-MYH11 knock-in mouse model, comparison with Cbfb and Runx1 knockout mice, flow cytometry, gene expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis using multiple knockout backgrounds with specific phenotypic readouts; replicated across primitive and definitive hematopoiesis","pmids":["20007544"],"is_preprint":false},{"year":2009,"finding":"GATA-1 transcriptionally represses Cbfb expression by co-occupying PU.1 motif sequences near the Cbfb locus; conditional activation of PU.1 or knockdown of GATA-1 leads to derepression of Cbfb associated with increased histone H3K9 acetylation.","method":"Conditional PU.1-ER activation in MEL cells, siRNA knockdown of GATA-1, ChIP, reporter assays, gene expression arrays","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus siRNA rescue in a defined cell model; single lab, multiple methods","pmids":["19825991"],"is_preprint":false},{"year":2013,"finding":"CBFβ-SMMHC localizes to RUNX1-occupied promoters genome-wide, where it interacts with TAL1, FLI1, TBP-associated factors (TAFs), ERG, GATA2, PU.1, EP300, and HDAC1; the majority of CBFβ-SMMHC target genes (including ID1, LMO1, JAG1) are actively transcribed and are repressed upon fusion protein knockdown, indicating CBFβ-SMMHC maintains expression of stem cell self-renewal genes.","method":"Genome-wide ChIP-seq, quantitative interaction proteomics (mass spectrometry), transcriptional analysis with shRNA knockdown of CBFB-MYH11","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide binding analysis combined with quantitative proteomics interactome and transcriptional perturbation; multiple orthogonal methods in a single rigorous study","pmids":["24002588"],"is_preprint":false},{"year":2015,"finding":"Cbfb stabilizes all three Runx family proteins (Runx1, Runx2, Runx3) in chondrocytes and osteoblasts; conditional deletion of Cbfb in mesenchymal cells reduces Runx protein levels and impairs chondrocyte differentiation/proliferation and osteoblast differentiation; Runx2 protein stability is less dependent on Cbfb in calvariae than in cartilaginous limb skeletons.","method":"Conditional Cbfb knockout (Dermo1-Cre), Western blot for Runx protein levels, protein stability assay, reporter assays for Ihh/Col10a1/Bglap2 promoters, in vitro differentiation","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with multiple tissue-specific phenotypes, protein stability assay, reporter assays, and in vitro differentiation experiments; single lab but multiple orthogonal methods","pmids":["25262822"],"is_preprint":false},{"year":2015,"finding":"Runx1 activity is critical for Cbfb-MYH11-induced hematopoietic defects and leukemogenesis; loss of Runx1 (homozygous null or dominant-negative allele) rescues differentiation defects induced by Cbfb-MYH11 during primitive hematopoiesis and significantly reduces proliferation/differentiation defects in definitive hematopoiesis; Cbfb-MYH11-induced leukemia has longer latency in Runx1-deficient mice.","method":"Genetic epistasis: Cbfb-MYH11 knock-in combined with Runx1 null and dominant-negative alleles; mouse leukemia latency analysis, flow cytometry","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous genetic epistasis with multiple Runx1 alleles and defined hematopoietic and leukemia latency phenotypes; strong mechanistic evidence for pathway placement","pmids":["25742748"],"is_preprint":false},{"year":2017,"finding":"CHD7 interacts with CBFβ-SMMHC through RUNX1 and enhances transcriptional activity of RUNX1 and CBFβ-SMMHC on target genes (e.g., Csf1r); Chd7 deficiency delays Cbfb-MYH11-induced leukemia by reducing LK progenitor proliferation and altering RUNX1 target gene expression.","method":"Co-immunoprecipitation (CHD7–CBFβ-SMMHC–RUNX1 interaction), conditional Chd7 knockout in Cbfb-MYH11 knock-in mice, in vitro transcription reporter assay, BrdU incorporation, RNA-seq, leukemia latency analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP interaction plus genetic epistasis with conditional knockout, reporter assay, and RNA-seq; multiple orthogonal methods in a single study","pmids":["29018080"],"is_preprint":false},{"year":2017,"finding":"p53 induced by RUNX1 depletion directly binds to the CBFB promoter and stimulates CBFB transcription and translation; increased CBFB in turn acts as a platform for RUNX1 stabilization, creating a compensatory RUNX1-p53-CBFB feedback loop that confers resistance to chemotherapy in AML cells.","method":"RUNX1 siRNA knockdown, chromatin immunoprecipitation (p53 binding to CBFB promoter), reporter assay, Western blot for protein levels, AML patient sample analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus knockdown experiments establishing direct p53–CBFB promoter interaction; single lab, multiple methods","pmids":["29192243"],"is_preprint":false},{"year":2019,"finding":"CBFB binds to hundreds of mRNAs via hnRNPK in the cytoplasm and enhances their translation through eIF4B; among the translationally regulated targets is RUNX1 mRNA itself. Nuclear CBFB/RUNX1 complex transcriptionally represses the NOTCH signaling pathway in breast cancer.","method":"RNA immunoprecipitation followed by deep sequencing (RIP-seq), co-immunoprecipitation (CBFB–hnRNPK, CBFB–eIF4B), polysome profiling, reporter assay, CBFB knockdown/rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — RIP-seq, co-IP, polysome profiling, and reporter assays collectively defining a noncanonical translation regulatory mechanism with multiple orthogonal methods in a single study","pmids":["31061501"],"is_preprint":false},{"year":2019,"finding":"Cbfb is an essential cofactor of Runx1 in anterior palatogenesis; Cbfb mutant mice exhibit failed epithelial disintegration at the anterior palate, disrupted TGFB3 expression, and impaired Stat3 phosphorylation; folic acid rescues anterior cleft palate by restoring Stat3 phosphorylation and Tgfb3 expression, placing Cbfb in a Runx1/Cbfb–Stat3–Tgfb3 signaling axis.","method":"Cbfb conditional knockout mouse, in vitro palatal fusion rescue with TGFB3 protein, folic acid treatment, immunostaining for phospho-Stat3 and TGFB3","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with defined phenotype, pathway rescue by TGFB3 and folic acid, phospho-signaling analysis; single lab, multiple orthogonal approaches","pmids":["31171577"],"is_preprint":false},{"year":2021,"finding":"CBFB cooperates with p53 to maintain TAp73 expression; loss of either CBFB or p53 leads to TAp73 depletion; TAp73 re-expression abrogates the tumorigenic effect of CBFB deletion; TAp73 loss enhances tumorigenesis driven by NOTCH3 overexpression (a downstream event of CBFB loss).","method":"Integrated genomic analysis of CBFB/TP53 mutual exclusivity, CBFB and p53 knockdown, TAp73 re-expression rescue, xenograft tumor growth, immunohistochemistry","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown and rescue experiments with xenograft validation; single lab, multiple methods","pmids":["33945523"],"is_preprint":false},{"year":2021,"finding":"The CBFB-MYH11 fusion protein sequesters RUNX1 in the cytoplasm, preventing RUNX1 from interacting with and recruiting DNMT3A to its target genes; CBFB-MYH11 expression phenocopies DNMT3A loss-of-function in producing DNA hypomethylation at RUNX1 target genes; CBFB-MYH11 mutations and DNMT3A mutations are mutually exclusive in AML.","method":"Co-immunoprecipitation (RUNX1–DNMT3A interaction), CBFB-MYH11 expression system, DNA methylation analysis, gene expression profiling, mutual exclusivity analysis in patient cohorts","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP defining direct RUNX1–DNMT3A interaction plus expression-system phenocopy and patient mutual exclusivity; single lab, multiple methods","pmids":["34336831"],"is_preprint":false},{"year":2023,"finding":"CBFB localizes to mitochondria and functions in mitochondrial translation by enhancing the binding of mitochondrial mRNAs to TUFM (mitochondrial translation elongation factor); CBFB loss-of-function causes defective oxidative phosphorylation, Warburg effect, and autophagy/mitophagy addiction; this mitochondrial translation role cooperates with oncogenic PIK3CA mutations in breast cancer progression.","method":"Integrated omics (proteomics interactome of CBFB), mitochondrial fractionation, RIP demonstrating CBFB–mRNA–TUFM interaction, metabolic assays (OXPHOS, glycolysis), autophagy flux assays, mouse tumor models and PDX","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mitochondrial localization by fractionation, RIP demonstrating mRNA binding to TUFM, metabolic phenotyping, and in vivo PDX models; multiple orthogonal methods establishing a noncanonical CBFB function","pmids":["36799863"],"is_preprint":false},{"year":2023,"finding":"Using proximity biotinylation (TurboID) in primary hematopoietic cells, CBFB::MYH11 interacting proteins are largely cytoplasmic, owing to interaction of the MYH11 domain with cytoplasmic myosin-related proteins; the CBFB domain of CBFB::MYH11 sequesters RUNX1 in cytoplasmic aggregates in primary human AML cells; paradoxically, CBFB::MYH11 expression is associated with increased RUNX1/2 transcription, suggesting a compensatory feedback mechanism.","method":"TurboID proximity biotinylation fused to oncofusion proteins in primary murine hematopoietic cells, mass spectrometry interactome, immunofluorescence/subcellular fractionation in primary human AML cells","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — unbiased proximity biotinylation proteomics plus orthogonal validation by immunofluorescence in primary human cells; rigorously controlled comparison with other AML oncofusions","pmids":["38061017"],"is_preprint":false},{"year":2020,"finding":"A nonameric peptide derived from the CBFB-MYH11 fusion junction is naturally presented on HLA-B*40:01 on AML blasts and is immunogenic; high-avidity CD8+ T cell clones recognizing this neoepitope kill CBFB-MYH11+ AML cells in vitro and control AML in a patient-derived xenograft model in vivo.","method":"HLA peptide elution and mass spectrometry (neoantigen presentation), T cell cloning, cytotoxicity assays, TCR transduction, PDX mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mass spectrometry confirmation of natural antigen presentation, functional T cell killing assays, and in vivo PDX validation; multiple orthogonal methods","pmids":["32831296"],"is_preprint":false},{"year":2020,"finding":"CBFB interacts with RUNX2 (co-immunoprecipitation confirmed), and miR-27b targets CBFB to inhibit hypertrophic chondrocyte differentiation of human BMSCs; CBFB knockdown by shRNA increases COL2/SOX9 expression and decreases COL10 expression.","method":"Co-immunoprecipitation (CBFB–RUNX2), luciferase reporter assay (miR-27b targeting CBFB 3'-UTR), shRNA knockdown of CBFB, RT-qPCR and Western blot, in vivo cartilage implant model","journal":"Stem cell research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirming CBFB–RUNX2 interaction, luciferase reporter, and shRNA phenotype with in vivo validation; single lab, multiple methods","pmids":["32917285"],"is_preprint":false}],"current_model":"CBFB encodes the beta subunit of core-binding factor (CBF), which heterodimerizes with RUNX family proteins (RUNX1/2/3) via a conserved interaction surface to enhance their DNA binding and stabilize them against ubiquitin-mediated proteasomal degradation; together with CBF-A (NF-YB) and CBF-C (NF-YC) it also forms a trimeric CCAAT-binding complex with two additive transcriptional activation domains; the leukemia-associated CBFB-MYH11 fusion protein sequesters RUNX1 in cytoplasmic aggregates through its myosin tail, preventing RUNX1 from recruiting DNMT3A to target gene promoters and dominantly repressing CBF-dependent transcription, while also driving self-renewal gene expression; beyond its nuclear transcriptional role, CBFB localizes to mitochondria and promotes translation of mitochondrial mRNAs through TUFM, and in the cytoplasm it binds mRNAs via hnRNPK to enhance cap-dependent translation through eIF4B, collectively functioning as a tumor suppressor in breast and other cancers."},"narrative":{"mechanistic_narrative":"CBFB encodes the non-DNA-binding beta subunit of core-binding factor, which heterodimerizes with RUNX family transcription factors to enhance their DNA binding and protein stability, and serves as a master regulator across hematopoiesis, skeletal development, and craniofacial morphogenesis [PMID:11110689, PMID:12811622, PMID:25262822]. Within the CCAAT-binding context, CBF-B associates with the CBF-A/CBF-C (NF-YB/NF-YC) histone-fold heterodimer—binding the hybrid surface they generate rather than either subunit alone—to form a heterotrimeric DNA-binding complex, and contributes one of two additive transcriptional activation domains [PMID:7878029, PMID:8754798, PMID:8662945]. As a RUNX partner, CBFB binds RUNX1/2/3 to enhance their DNA binding and protect them from ubiquitin-mediated proteasomal degradation, an activity essential for Runx1-dependent hematopoiesis, Runx2-driven osteoblast and chondrocyte differentiation, and Runx1-dependent anterior palatogenesis through a Stat3–Tgfb3 axis [PMID:11110689, PMID:17379770, PMID:25262822, PMID:31171577, PMID:32917285]. Beyond its nuclear role, CBFB functions in the cytoplasm by binding hundreds of mRNAs via hnRNPK to promote cap-dependent translation through eIF4B, and localizes to mitochondria where it enhances binding of mitochondrial mRNAs to the elongation factor TUFM to support oxidative phosphorylation, with loss of these activities cooperating with oncogenic PIK3CA in breast cancer—establishing CBFB as a tumor suppressor [PMID:31061501, PMID:36799863]. The leukemia-associated CBFB-MYH11 fusion generated by inv(16) acts as a dominant-negative oncoprotein that sequesters RUNX1 in cytoplasmic aggregates via its myosin tail, blocking RUNX1 from recruiting DNMT3A to target genes, while also independently driving expression of stem-cell self-renewal genes through occupancy of RUNX1 sites with cofactors including TAL1, FLI1, ERG, GATA2, PU.1, EP300, and CHD7 [PMID:8929537, PMID:24002588, PMID:34336831, PMID:38061017].","teleology":[{"year":1995,"claim":"Established the architecture of the CCAAT-binding CBF complex, showing CBF-B cannot bind DNA or individual subunits alone but joins a preformed CBF-A/CBF-C heterodimer.","evidence":"Recombinant protein reconstitution, EMSA, and immunoprecipitation with purified E. coli-expressed subunits","pmids":["7878029"],"confidence":"High","gaps":["Did not define the interaction domains structurally","Relationship to RUNX-based CBF complexes not addressed"]},{"year":1996,"claim":"Defined the molecular basis of CBF assembly and its transactivation capacity, mapping the histone-fold-dependent A/C heterodimer that creates a hybrid surface for CBF-B and locating two additive activation domains.","evidence":"Cross-linking, immunoprecipitation, CBF-C mutagenesis, yeast two-hybrid, and in vitro transcription reconstitution with deletion mutants","pmids":["8754798","8662945"],"confidence":"High","gaps":["In vitro activation domains not validated in cellular promoter context","No structural model of the trimeric surface"]},{"year":1996,"claim":"Demonstrated that the inv(16) CBFB-MYH11 fusion acts as a dominant-negative oncoprotein, with knock-in mice phenocopying the hematopoietic block of Cbfb or Runx1 null embryos.","evidence":"Knock-in mouse model, chimeric mouse analysis, embryo phenotyping; Western blot/EMSA/IF in patient nuclei","pmids":["8929537","8818654"],"confidence":"High","gaps":["Molecular mechanism of dominant inhibition not yet resolved","Subcellular basis of RUNX1 inhibition undefined"]},{"year":2001,"claim":"Localized the dominant-negative mechanism to cytoplasmic sequestration of RUNX1 by CBFB-MYH11, with concomitant loss of transactivation and altered cell-cycle/apoptotic responses.","evidence":"Cell transfection and reporter assays (review summarizing prior experiments)","pmids":["11561156"],"confidence":"Medium","gaps":["Review-level synthesis rather than a single primary dataset","Structural determinant of sequestration in the MYH11 tail not yet mapped"]},{"year":2002,"claim":"Defined where in the hematopoietic hierarchy CBFB acts and where the fusion blocks differentiation, placing the defect at the stem/progenitor level.","evidence":"Cbfb-GFP knock-in reporter mouse with flow cytometry, compared to Cbfb-MYH11 knock-in embryos","pmids":["12239155"],"confidence":"High","gaps":["Did not address adult/definitive leukemogenesis directly","Cell-intrinsic vs niche contributions not separated"]},{"year":2003,"claim":"Extended CBFB function beyond blood to skeletal development by showing it is required for both Runx1 and Runx2 activity in osteoblast and chondrocyte differentiation.","evidence":"Cbfb knockout mouse rescue and genetic phenotyping of skeletal and hematopoietic tissues","pmids":["12811622"],"confidence":"Medium","gaps":["Molecular mechanism (stabilization vs DNA binding) not yet distinguished","Review-level summary"]},{"year":2005,"claim":"Revealed a non-transcriptional leukemogenic mechanism: CBFB-MYH11 suppresses CEBPA post-translationally by inducing calreticulin, an inhibitor of CEBPA translation.","evidence":"Conditional CBFB-SMMHC expression in U937 cells, Western blot, EMSA, calreticulin siRNA rescue, patient samples","pmids":["15855281"],"confidence":"High","gaps":["Mechanism by which the fusion induces calreticulin unknown","In vivo relevance to leukemia not established here"]},{"year":2007,"claim":"Defined the biochemical basis of CBFB's role in osteogenesis as stabilization of RUNX2 against ubiquitin-mediated degradation.","evidence":"Adenoviral Cbfb/Cbfa-1 overexpression in C3H10T1/2 and human BMSCs, ubiquitination and protein stability assays","pmids":["17379770"],"confidence":"Medium","gaps":["E3 ligase mediating RUNX2 degradation not identified","Single overexpression system"]},{"year":2009,"claim":"Showed CBFB-MYH11 has leukemogenic activities independent of dominant RUNX1 repression, producing unique gene-expression and progenitor phenotypes absent in knockout mice.","evidence":"Cbfb-MYH11 knock-in mice vs Cbfb and Runx1 knockouts, flow cytometry, gene expression analysis","pmids":["20007544"],"confidence":"High","gaps":["Molecular drivers of the repression-independent program not identified here","Restricted to embryonic hematopoiesis readouts"]},{"year":2009,"claim":"Identified upstream transcriptional control of CBFB, with GATA-1 repressing the locus by co-occupying PU.1 motifs.","evidence":"Conditional PU.1-ER activation and GATA-1 siRNA in MEL cells, ChIP, reporter assays, expression arrays","pmids":["19825991"],"confidence":"Medium","gaps":["Physiological significance in normal hematopoiesis unclear","Single cell-line model"]},{"year":2013,"claim":"Established the genome-wide, gain-of-function transcriptional program of CBFB-MYH11, showing it maintains self-renewal gene expression at RUNX1 sites with a defined cofactor network.","evidence":"ChIP-seq, quantitative interaction proteomics, and shRNA knockdown transcriptional analysis","pmids":["24002588"],"confidence":"High","gaps":["Direct vs indirect cofactor recruitment not fully resolved","Causal contribution of individual targets to leukemia untested here"]},{"year":2015,"claim":"Consolidated CBFB as a pan-RUNX stabilizer in skeletal tissue and showed RUNX1 activity is required for CBFB-MYH11 leukemogenesis via genetic epistasis.","evidence":"Conditional Cbfb knockout (Dermo1-Cre) with protein stability/reporter assays; Cbfb-MYH11 combined with Runx1 null and dominant-negative alleles, leukemia latency","pmids":["25262822","25742748"],"confidence":"High","gaps":["Tissue-specific differences in RUNX2 dependence not mechanistically explained","Residual leukemia in Runx1-deficient background implies additional drivers"]},{"year":2017,"claim":"Identified CHD7 as a cofactor enhancing RUNX1/CBFB-MYH11 transcription and a p53-RUNX1-CBFB feedback loop conferring chemoresistance.","evidence":"Co-IP, conditional Chd7 knockout in Cbfb-MYH11 mice, reporter/RNA-seq; RUNX1 siRNA, p53 ChIP on CBFB promoter, reporter, patient samples","pmids":["29018080","29192243"],"confidence":"High","gaps":["Therapeutic exploitability of the feedback loop not tested","Generality of CHD7 dependence across genotypes unclear"]},{"year":2019,"claim":"Uncovered a cytoplasmic, non-canonical CBFB function in mRNA translation via hnRNPK/eIF4B and a tumor-suppressive nuclear role repressing NOTCH in breast cancer.","evidence":"RIP-seq, CBFB-hnRNPK and CBFB-eIF4B co-IP, polysome profiling, reporter assays, knockdown/rescue","pmids":["31061501"],"confidence":"High","gaps":["How CBFB partitions between nuclear and cytoplasmic roles unknown","Selectivity for target mRNAs not fully defined"]},{"year":2019,"claim":"Placed CBFB in a Runx1-Stat3-Tgfb3 craniofacial signaling axis required for anterior palatogenesis, with folic acid rescue.","evidence":"Cbfb conditional knockout mouse, palatal fusion rescue with TGFB3, folic acid treatment, phospho-Stat3/TGFB3 immunostaining","pmids":["31171577"],"confidence":"Medium","gaps":["Direct transcriptional targets in the axis not mapped","Mechanism of folic acid rescue unresolved"]},{"year":2020,"claim":"Demonstrated the CBFB-MYH11 fusion junction generates a presented, immunogenic neoantigen targetable by cytotoxic T cells, and that miR-27b regulates CBFB in chondrocyte differentiation.","evidence":"HLA peptide elution/MS, T cell cloning and cytotoxicity, TCR transduction, PDX; CBFB-RUNX2 co-IP, miR-27b luciferase reporter, shRNA knockdown, cartilage implant","pmids":["32831296","32917285"],"confidence":"High","gaps":["Clinical efficacy of neoantigen-directed therapy untested","HLA restriction limits applicability"]},{"year":2021,"claim":"Mechanistically connected the fusion's cytoplasmic RUNX1 sequestration to epigenetic dysregulation (blocked DNMT3A recruitment) and defined a CBFB-p53-TAp73 tumor-suppressive network.","evidence":"RUNX1-DNMT3A co-IP, CBFB-MYH11 expression, methylation/expression profiling, patient mutual exclusivity; CBFB/p53 knockdown, TAp73 rescue, xenografts","pmids":["34336831","33945523"],"confidence":"Medium","gaps":["Direct vs indirect DNMT3A recruitment effects not fully separated","Single-lab knockdown/rescue systems"]},{"year":2023,"claim":"Defined a mitochondrial translation role for CBFB via TUFM and used unbiased proximity proteomics to confirm the fusion's interactome is predominantly cytoplasmic, sequestering RUNX1 in aggregates.","evidence":"Proteomics interactome, mitochondrial fractionation, RIP (CBFB-mRNA-TUFM), metabolic/autophagy assays, PDX; TurboID proximity biotinylation in primary cells with IF validation","pmids":["36799863","38061017"],"confidence":"High","gaps":["How CBFB is imported to and retained in mitochondria unknown","Paradoxical increased RUNX1/2 transcription with fusion not mechanistically resolved"]},{"year":null,"claim":"How CBFB is partitioned among its nuclear transcriptional, cytoplasmic translational, and mitochondrial roles—and how these are coordinately regulated in normal versus malignant cells—remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural or regulatory mechanism governing CBFB compartmentalization identified","Relative contribution of each subcellular function to tumor suppression unquantified","No structural model of CBFB-MYH11 cytoplasmic aggregates"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,10,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[18,22]},{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[18,22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18,23]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,13]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,14,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,13,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[18,22]}],"complexes":["core-binding factor (CBF/RUNX)","CCAAT-binding factor (NF-Y) trimer"],"partners":["RUNX1","RUNX2","RUNX3","HNRNPK","EIF4B","TUFM","CHD7","NFYC"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13951","full_name":"Core-binding factor subunit beta","aliases":["Polyomavirus enhancer-binding protein 2 beta subunit","PEA2-beta","PEBP2-beta","SL3-3 enhancer factor 1 subunit beta","SL3/AKV core-binding factor beta subunit"],"length_aa":182,"mass_kda":21.5,"function":"Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation (Microbial infection) Following infection, hijacked by the HIV-1 Vif protein, leading to the formation a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex) that catalyzes ubiquitination and degradation of APOBEC3F and APOBEC3G (PubMed:22190037, PubMed:31792451, PubMed:36598981, PubMed:36754086, PubMed:37419875). The complex can also ubiquitinate APOBEC3H to some extent (PubMed:37640699). Association with HIV-1 Vif protein also inhibits the transcription coactivator activity of CBFB/CBF-beta (PubMed:22190037)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13951/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CBFB","classification":"Not Classified","n_dependent_lines":288,"n_total_lines":1208,"dependency_fraction":0.23841059602649006},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CBFB","total_profiled":1310},"omim":[{"mim_id":"620099","title":"CLEIDOCRANIAL DYSPLASIA 2; CLCD2","url":"https://www.omim.org/entry/620099"},{"mim_id":"614541","title":"CHROMOSOME 16q22 DELETION SYNDROME","url":"https://www.omim.org/entry/614541"},{"mim_id":"611614","title":"UTP3 SMALL SUBUNIT PROCESSOME COMPONENT; UTP3","url":"https://www.omim.org/entry/611614"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"607113","title":"APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3G; APOBEC3G","url":"https://www.omim.org/entry/607113"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CBFB"},"hgnc":{"alias_symbol":["PEBP2B"],"prev_symbol":[]},"alphafold":{"accession":"Q13951","domains":[{"cath_id":"2.40.250.10","chopping":"7-129","consensus_level":"high","plddt":91.9718,"start":7,"end":129}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13951","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13951-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13951-F1-predicted_aligned_error_v6.png","plddt_mean":85.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CBFB","jax_strain_url":"https://www.jax.org/strain/search?query=CBFB"},"sequence":{"accession":"Q13951","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13951.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13951/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13951"}},"corpus_meta":[{"pmid":"7878029","id":"PMC_7878029","title":"Recombinant rat CBF-C, the third subunit of CBF/NFY, allows formation of a protein-DNA complex with CBF-A and CBF-B and with yeast HAP2 and HAP3.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7878029","citation_count":253,"is_preprint":false},{"pmid":"8929537","id":"PMC_8929537","title":"Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8929537","citation_count":249,"is_preprint":false},{"pmid":"29386218","id":"PMC_29386218","title":"Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29386218","citation_count":185,"is_preprint":false},{"pmid":"12811622","id":"PMC_12811622","title":"Requisite roles of Runx2 and Cbfb in skeletal development.","date":"2003","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12811622","citation_count":171,"is_preprint":false},{"pmid":"8754798","id":"PMC_8754798","title":"Determination of functional domains in the C subunit of the CCAAT-binding factor (CBF) necessary for formation of a CBF-DNA complex: CBF-B interacts simultaneously with both the CBF-A and CBF-C subunits to form a heterotrimeric CBF molecule.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8754798","citation_count":130,"is_preprint":false},{"pmid":"29902450","id":"PMC_29902450","title":"Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29902450","citation_count":113,"is_preprint":false},{"pmid":"15585652","id":"PMC_15585652","title":"Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15585652","citation_count":112,"is_preprint":false},{"pmid":"15044690","id":"PMC_15044690","title":"Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15044690","citation_count":111,"is_preprint":false},{"pmid":"19156145","id":"PMC_19156145","title":"Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19156145","citation_count":96,"is_preprint":false},{"pmid":"15855281","id":"PMC_15855281","title":"CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15855281","citation_count":80,"is_preprint":false},{"pmid":"25262822","id":"PMC_25262822","title":"Cbfb regulates bone development by stabilizing Runx family proteins.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25262822","citation_count":77,"is_preprint":false},{"pmid":"9586906","id":"PMC_9586906","title":"Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?","date":"1998","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9586906","citation_count":75,"is_preprint":false},{"pmid":"7577615","id":"PMC_7577615","title":"Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.","date":"1995","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/7577615","citation_count":75,"is_preprint":false},{"pmid":"32831296","id":"PMC_32831296","title":"CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32831296","citation_count":73,"is_preprint":false},{"pmid":"31061501","id":"PMC_31061501","title":"The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31061501","citation_count":71,"is_preprint":false},{"pmid":"8662945","id":"PMC_8662945","title":"The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8662945","citation_count":70,"is_preprint":false},{"pmid":"24002588","id":"PMC_24002588","title":"CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24002588","citation_count":69,"is_preprint":false},{"pmid":"15386419","id":"PMC_15386419","title":"Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15386419","citation_count":65,"is_preprint":false},{"pmid":"7795233","id":"PMC_7795233","title":"RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7795233","citation_count":60,"is_preprint":false},{"pmid":"15156186","id":"PMC_15156186","title":"Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15156186","citation_count":56,"is_preprint":false},{"pmid":"8818654","id":"PMC_8818654","title":"Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.","date":"1996","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8818654","citation_count":55,"is_preprint":false},{"pmid":"29932212","id":"PMC_29932212","title":"CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.","date":"2018","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29932212","citation_count":55,"is_preprint":false},{"pmid":"26450370","id":"PMC_26450370","title":"MicroRNA-145 regulates osteoblastic differentiation by targeting the transcription factor Cbfb.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/26450370","citation_count":48,"is_preprint":false},{"pmid":"25742748","id":"PMC_25742748","title":"Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25742748","citation_count":47,"is_preprint":false},{"pmid":"12239155","id":"PMC_12239155","title":"Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12239155","citation_count":46,"is_preprint":false},{"pmid":"20007544","id":"PMC_20007544","title":"Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20007544","citation_count":43,"is_preprint":false},{"pmid":"22160378","id":"PMC_22160378","title":"KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22160378","citation_count":43,"is_preprint":false},{"pmid":"17287858","id":"PMC_17287858","title":"Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17287858","citation_count":43,"is_preprint":false},{"pmid":"23160462","id":"PMC_23160462","title":"inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23160462","citation_count":37,"is_preprint":false},{"pmid":"11110689","id":"PMC_11110689","title":"Zebrafish homolog of the leukemia gene CBFB: its expression during embryogenesis and its relationship to scl and gata-1 in hematopoiesis.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11110689","citation_count":36,"is_preprint":false},{"pmid":"29192243","id":"PMC_29192243","title":"Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29192243","citation_count":29,"is_preprint":false},{"pmid":"11241787","id":"PMC_11241787","title":"Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.","date":"2001","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11241787","citation_count":29,"is_preprint":false},{"pmid":"33159035","id":"PMC_33159035","title":"circ-CBFB upregulates p66Shc to perturb mitochondrial dynamics in APAP-induced liver injury.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33159035","citation_count":28,"is_preprint":false},{"pmid":"11561156","id":"PMC_11561156","title":"Function of the inv(16) fusion gene CBFB-MYH11.","date":"2001","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11561156","citation_count":26,"is_preprint":false},{"pmid":"34027799","id":"PMC_34027799","title":"Circular RNA_0062582 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via regulation of microRNA-145/CBFB axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34027799","citation_count":26,"is_preprint":false},{"pmid":"17022082","id":"PMC_17022082","title":"Core binding factor beta (CBFB) haploinsufficiency due to an interstitial deletion at 16q21q22 resulting in delayed cranial ossification, cleft palate, congenital heart anomalies, and feeding difficulties but favorable outcome.","date":"2006","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17022082","citation_count":26,"is_preprint":false},{"pmid":"29018080","id":"PMC_29018080","title":"Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29018080","citation_count":25,"is_preprint":false},{"pmid":"12139724","id":"PMC_12139724","title":"Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.","date":"2002","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/12139724","citation_count":25,"is_preprint":false},{"pmid":"28253536","id":"PMC_28253536","title":"Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.","date":"2017","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28253536","citation_count":25,"is_preprint":false},{"pmid":"19825991","id":"PMC_19825991","title":"PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19825991","citation_count":24,"is_preprint":false},{"pmid":"17379770","id":"PMC_17379770","title":"Cbfb enhances the osteogenic differentiation of both human and mouse mesenchymal stem cells induced by Cbfa-1 via reducing its ubiquitination-mediated degradation.","date":"2007","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/17379770","citation_count":24,"is_preprint":false},{"pmid":"30742053","id":"PMC_30742053","title":"IL1RL1 is dynamically expressed on Cbfb-MYH11+ leukemia stem cells and promotes cell survival.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30742053","citation_count":21,"is_preprint":false},{"pmid":"28030795","id":"PMC_28030795","title":"AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28030795","citation_count":21,"is_preprint":false},{"pmid":"15566413","id":"PMC_15566413","title":"Large fontanelles are a shared feature of haploinsufficiency of RUNX2 and its co-activator CBFB.","date":"2004","source":"Congenital anomalies","url":"https://pubmed.ncbi.nlm.nih.gov/15566413","citation_count":21,"is_preprint":false},{"pmid":"33505358","id":"PMC_33505358","title":"The p53/miR-145a Axis Promotes Cellular Senescence and Inhibits Osteogenic Differentiation by Targeting Cbfb in Mesenchymal Stem Cells.","date":"2021","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33505358","citation_count":20,"is_preprint":false},{"pmid":"16504290","id":"PMC_16504290","title":"Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/16504290","citation_count":20,"is_preprint":false},{"pmid":"11920247","id":"PMC_11920247","title":"Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis.","date":"2001","source":"The hematology journal : the official journal of the European Haematology Association","url":"https://pubmed.ncbi.nlm.nih.gov/11920247","citation_count":20,"is_preprint":false},{"pmid":"20513535","id":"PMC_20513535","title":"Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review.","date":"2010","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20513535","citation_count":19,"is_preprint":false},{"pmid":"7607682","id":"PMC_7607682","title":"Structure of the leukemia-associated human CBFB gene.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7607682","citation_count":19,"is_preprint":false},{"pmid":"28299658","id":"PMC_28299658","title":"Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/28299658","citation_count":18,"is_preprint":false},{"pmid":"17185462","id":"PMC_17185462","title":"CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17185462","citation_count":18,"is_preprint":false},{"pmid":"31671434","id":"PMC_31671434","title":"Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen.","date":"2020","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31671434","citation_count":17,"is_preprint":false},{"pmid":"31624376","id":"PMC_31624376","title":"Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/31624376","citation_count":17,"is_preprint":false},{"pmid":"32917285","id":"PMC_32917285","title":"MicroRNA-27b targets CBFB to inhibit differentiation of human bone marrow mesenchymal stem cells into hypertrophic chondrocytes.","date":"2020","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32917285","citation_count":17,"is_preprint":false},{"pmid":"10959099","id":"PMC_10959099","title":"CBFB/MYH11 fusion in a patient with AML-M4Eo and cytogenetically normal chromosomes 16.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10959099","citation_count":17,"is_preprint":false},{"pmid":"28906004","id":"PMC_28906004","title":"Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion.","date":"2015","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28906004","citation_count":16,"is_preprint":false},{"pmid":"33945523","id":"PMC_33945523","title":"CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33945523","citation_count":15,"is_preprint":false},{"pmid":"34336831","id":"PMC_34336831","title":"CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34336831","citation_count":14,"is_preprint":false},{"pmid":"19215788","id":"PMC_19215788","title":"Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits.","date":"2009","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19215788","citation_count":14,"is_preprint":false},{"pmid":"15381374","id":"PMC_15381374","title":"Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16.","date":"2004","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15381374","citation_count":14,"is_preprint":false},{"pmid":"36362086","id":"PMC_36362086","title":"Different Requirements of CBFB and RUNX2 in Skeletal Development among Calvaria, Limbs, Vertebrae and Ribs.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362086","citation_count":13,"is_preprint":false},{"pmid":"36799863","id":"PMC_36799863","title":"Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36799863","citation_count":13,"is_preprint":false},{"pmid":"17052753","id":"PMC_17052753","title":"Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.","date":"2006","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/17052753","citation_count":13,"is_preprint":false},{"pmid":"8751466","id":"PMC_8751466","title":"The gene product of CBFB-MYH11.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8751466","citation_count":12,"is_preprint":false},{"pmid":"35920438","id":"PMC_35920438","title":"Circ-CBFB exacerbates hypoxia/reoxygenation-triggered cardiomyocyte injury via regulating miR-495-3p in a VDAC1-dependent manner.","date":"2022","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35920438","citation_count":11,"is_preprint":false},{"pmid":"31171577","id":"PMC_31171577","title":"Anterior cleft palate due to Cbfb deficiency and its rescue by folic acid.","date":"2019","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31171577","citation_count":11,"is_preprint":false},{"pmid":"31865182","id":"PMC_31865182","title":"RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.","date":"2019","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31865182","citation_count":11,"is_preprint":false},{"pmid":"25266220","id":"PMC_25266220","title":"CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.","date":"2014","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25266220","citation_count":11,"is_preprint":false},{"pmid":"38061017","id":"PMC_38061017","title":"Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38061017","citation_count":10,"is_preprint":false},{"pmid":"24342433","id":"PMC_24342433","title":"Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24342433","citation_count":10,"is_preprint":false},{"pmid":"35445594","id":"PMC_35445594","title":"Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions.","date":"2022","source":"Turkish journal of haematology : official journal of Turkish Society of Haematology","url":"https://pubmed.ncbi.nlm.nih.gov/35445594","citation_count":9,"is_preprint":false},{"pmid":"11063812","id":"PMC_11063812","title":"Deletion of 3'-CBFB gene in association with an inversion (16)(p13q22) and a loss of the Y chromosome in a 2-year-Old child with acute myelogenous leukemia-M4.","date":"2000","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11063812","citation_count":9,"is_preprint":false},{"pmid":"33489389","id":"PMC_33489389","title":"De Novo Acute Myeloid Leukemia with Combined CBFB-MYH11 and BCR-ABL1 Gene Rearrangements: A Case Report and Review of Literature.","date":"2020","source":"Case reports in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33489389","citation_count":8,"is_preprint":false},{"pmid":"12034528","id":"PMC_12034528","title":"Chromosome 16 inversion-associated translocations in acute myeloid leukemia elucidated using a dual-color CBFB DNA probe.","date":"2002","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12034528","citation_count":8,"is_preprint":false},{"pmid":"18328953","id":"PMC_18328953","title":"Banding and molecular cytogenetic studies detected a CBFB-MYH11 fusion gene that appeared as abnormal chromosomes 1 and 16 in a baby with acute myeloid leukemia FAB M4-Eo.","date":"2008","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18328953","citation_count":8,"is_preprint":false},{"pmid":"37225965","id":"PMC_37225965","title":"Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/37225965","citation_count":7,"is_preprint":false},{"pmid":"36241386","id":"PMC_36241386","title":"Heterozygous pathogenic variants involving CBFB cause a new skeletal disorder resembling cleidocranial dysplasia.","date":"2022","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36241386","citation_count":7,"is_preprint":false},{"pmid":"25410786","id":"PMC_25410786","title":"Runx/Cbfb signaling regulates postnatal development of granular convoluted tubule in the mouse submandibular gland.","date":"2014","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/25410786","citation_count":7,"is_preprint":false},{"pmid":"32015759","id":"PMC_32015759","title":"Acute myeloid leukemia with inv(16)(p13.1q22) and deletion of the 5'MYH11/3'CBFB gene fusion: a report of two cases and literature review.","date":"2020","source":"Molecular cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/32015759","citation_count":7,"is_preprint":false},{"pmid":"40304077","id":"PMC_40304077","title":"Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia.","date":"2025","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/40304077","citation_count":6,"is_preprint":false},{"pmid":"37807922","id":"PMC_37807922","title":"Multiple roles of LncRNA-BMNCR on cell proliferation and apoptosis by targeting miR-145/CBFB axis in BMECs.","date":"2023","source":"The veterinary quarterly","url":"https://pubmed.ncbi.nlm.nih.gov/37807922","citation_count":6,"is_preprint":false},{"pmid":"32711101","id":"PMC_32711101","title":"The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32711101","citation_count":6,"is_preprint":false},{"pmid":"34771519","id":"PMC_34771519","title":"CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34771519","citation_count":6,"is_preprint":false},{"pmid":"35903297","id":"PMC_35903297","title":"Cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of Breast Cancer Progression.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35903297","citation_count":6,"is_preprint":false},{"pmid":"8739792","id":"PMC_8739792","title":"CBFB/MYH11 fusion transcripts in a case of acute myelogenous leukemia (M1) with partial deletion of the long arm of chromosome 16.","date":"1996","source":"Internal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/8739792","citation_count":6,"is_preprint":false},{"pmid":"8847901","id":"PMC_8847901","title":"Clinical aspects of expression of inversion 16 chromosomal fusion transcript CBFB/MYH11 in acute myelogenous leukemia subtype M1 with abnormal bone marrow eosinophilia.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8847901","citation_count":5,"is_preprint":false},{"pmid":"17981216","id":"PMC_17981216","title":"Gain of multiple copies of the CBFB gene: a new genetic aberration in a case of granulocytic sarcoma.","date":"2007","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17981216","citation_count":5,"is_preprint":false},{"pmid":"40345240","id":"PMC_40345240","title":"A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping.","date":"2025","source":"Journal of the National Comprehensive Cancer Network : JNCCN","url":"https://pubmed.ncbi.nlm.nih.gov/40345240","citation_count":4,"is_preprint":false},{"pmid":"35184217","id":"PMC_35184217","title":"3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.","date":"2022","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35184217","citation_count":4,"is_preprint":false},{"pmid":"32570264","id":"PMC_32570264","title":"Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.","date":"2020","source":"Chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/32570264","citation_count":3,"is_preprint":false},{"pmid":"38801226","id":"PMC_38801226","title":"Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement.","date":"2024","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38801226","citation_count":2,"is_preprint":false},{"pmid":"35647832","id":"PMC_35647832","title":"CircRIP2 aggravates the deterioration of colorectal carcinoma by negatively regulating CBFB.","date":"2022","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35647832","citation_count":2,"is_preprint":false},{"pmid":"35794567","id":"PMC_35794567","title":"Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD-positive acute myeloid leukemia.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35794567","citation_count":2,"is_preprint":false},{"pmid":"37115099","id":"PMC_37115099","title":"Autophagy Inhibition as a Potential Therapeutic Strategy for Breast Cancer with Mitochondrial Translation Defect Caused by CBFB-Deficiency.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/37115099","citation_count":2,"is_preprint":false},{"pmid":"39894570","id":"PMC_39894570","title":"A Cryptic CBFB Deletion-Inversion Expands the Mutational Spectrum of Variants Associated With Cleidocranial Dysplasia.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39894570","citation_count":2,"is_preprint":false},{"pmid":"40882571","id":"PMC_40882571","title":"Unfavorable disease progression in patients with chronic myeloid leukemia and concurrent t(6;9) translocation (DEK::NUP214 fusion) or inversion 16 (CBFB::MYH11 fusion).","date":"2025","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40882571","citation_count":2,"is_preprint":false},{"pmid":"16502584","id":"PMC_16502584","title":"Diagnosis and monitoring of CBFB-MYH11-positive acute myeloid leukemia by qualitative and quantitative RT-PCR.","date":"2006","source":"Methods in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16502584","citation_count":2,"is_preprint":false},{"pmid":"25786458","id":"PMC_25786458","title":"Therapy-related leukemia with Inv(16)(p13.1q22) and type D CBFB/MYH11 developing after exposure to irinotecan-containing chemoradiotherapy.","date":"2015","source":"Internal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/25786458","citation_count":2,"is_preprint":false},{"pmid":"36011278","id":"PMC_36011278","title":"PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36011278","citation_count":1,"is_preprint":false},{"pmid":"35613501","id":"PMC_35613501","title":"Jumping translocation involving chromosome 13q in a patient with Crohn's Disease and inv(16)(p13.1q22)/CBFB-MYH11 acute myeloid leukemia.","date":"2022","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35613501","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52302,"output_tokens":7025,"usd":0.13114,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16114,"output_tokens":5794,"usd":0.11271,"stage2_stop_reason":"end_turn"},"total_usd":0.24385,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"CBF-C (NF-YC) is required together with CBF-A and CBF-B to form a CBF-DNA complex on CCAAT motifs; CBF-A and CBF-C interact with each other to form a heterodimer, and CBF-B associates with the CBF-A–CBF-C complex but not with either subunit individually.\",\n      \"method\": \"Recombinant protein reconstitution, EMSA, immunoprecipitation with purified subunits expressed in E. coli\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified recombinant proteins, EMSA, and immunoprecipitation; results replicated across multiple binding and co-complex experiments in a single rigorous study\",\n      \"pmids\": [\"7878029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CBF-B interacts simultaneously with both CBF-A and CBF-C subunits to form a heterotrimeric CBF molecule; the evolutionarily conserved histone-fold motif segment of CBF-C is necessary for CBF-DNA complex formation; CBF-A and CBF-C interact via histone-fold motifs to form a heterodimer that generates a hybrid surface for CBF-B interaction.\",\n      \"method\": \"Cross-linking, immunoprecipitation, mutational analysis of CBF-C, in vitro EMSA, yeast two-hybrid\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (crosslinking, IP, mutagenesis, yeast two-hybrid, in vitro assay) in one rigorous study defining interaction domains\",\n      \"pmids\": [\"8754798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CBF transcriptional activation is mediated by two distinct activation domains: one in CBF-B (N-terminal residues 1–224) and one in CBF-C (C-terminal residues 114–309); the two domains act additively in an in vitro transcription assay.\",\n      \"method\": \"In vitro transcription reconstitution with purified recombinant CBF subunits and deletion mutants, nuclear extract depletion/add-back assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with deletion mutants clearly defining activation domains; single lab but multiple constructs tested\",\n      \"pmids\": [\"8662945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The CBFB-MYH11 fusion oncogene, generated by inv(16), acts as a dominant negative inhibitor of normal CBFB/RUNX1 function; heterozygous knock-in of Cbfb-MYH11 in mice blocks definitive hematopoiesis, phenocopying homozygous deletion of Cbfb or Cbfa2 (AML1/RUNX1).\",\n      \"method\": \"Knock-in mouse model (homologous recombination ES cells), chimeric mouse analysis, embryo phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knock-in with defined hematopoietic phenotype, epistasis with Cbfb and Cbfa2 null alleles; replicated in subsequent studies\",\n      \"pmids\": [\"8929537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The CBFB-MYH11 fusion protein (CBFβ-SMMHC) is expressed as a ~70–95 kDa protein in inv(16) AML patient nuclei and forms a very high molecular weight protein-DNA complex in electrophoretic mobility shift assays; the protein is organized into novel structures within cell nuclei.\",\n      \"method\": \"Western blot with anti-CBFB and anti-MYH11 antisera, EMSA with patient nuclear extracts, immunofluorescence staining\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunofluorescence and EMSA in primary patient cells; single lab, multiple methods\",\n      \"pmids\": [\"8818654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Zebrafish cbfb protein binds to human CBFα2 (RUNX1) and enhances its DNA binding activity; cbfb is expressed in early hematopoietic progenitors in the intermediate cell mass, and its expression pattern resembles that of scl in hematopoietic mutants.\",\n      \"method\": \"Biochemical binding assay (recombinant protein), EMSA, in situ hybridization during zebrafish development, analysis in hematopoietic mutant zebrafish\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA-binding enhancement shown biochemically; in vivo expression in genetic mutants; single lab, two orthogonal methods\",\n      \"pmids\": [\"11110689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Expression of CBFB-MYH11 leads to sequestration of CBFα2 (RUNX1) in the cytoplasm, inhibits CBF-mediated transactivation, slows cell cycle progression, delays apoptotic response to DNA-damaging agents, and protects CBFα2 from degradation.\",\n      \"method\": \"In vitro cell transfection studies, reporter assays (review summarizing published experiments)\",\n      \"journal\": \"Current opinion in hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — review summarizing multiple cell-based experiments from prior publications; mechanisms individually supported by prior experimental work\",\n      \"pmids\": [\"11561156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cbfb is expressed in hematopoietic stem cells and progenitors during midgestation and in adult myeloid and lymphoid cells but not during terminal erythropoiesis; Cbfb-MYH11 blocks embryonic hematopoiesis at the stem-progenitor cell level.\",\n      \"method\": \"Cbfb-GFP knock-in mouse model, flow cytometry of hematopoietic populations, comparison with Cbfb-MYH11 knock-in embryos\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in reporter mouse with flow cytometry defining cell-specific expression and functional block; replicated in multiple knock-in models\",\n      \"pmids\": [\"12239155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cbfb is required for the functions of both Runx1 and Runx2 in hematopoiesis and skeletal development; Runx2/Cbfb heterodimers play essential roles in osteoblast differentiation and chondrocyte maturation.\",\n      \"method\": \"Cbfb knockout mouse rescue experiments, genetic analysis of skeletal and hematopoietic phenotypes\",\n      \"journal\": \"Journal of bone and mineral metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined skeletal/hematopoietic phenotype; single lab review summarizing prior experiments\",\n      \"pmids\": [\"12811622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CBFβ-SMMHC (CBFB-MYH11 fusion protein) suppresses CEBPA protein expression and binding activity post-translationally by inducing calreticulin, an inhibitor of CEBPA translation; CEBPA mRNA levels are unchanged, but protein and binding activity are reduced; siRNA knockdown of calreticulin restores CEBPA protein levels.\",\n      \"method\": \"Conditional expression of CBFB-SMMHC in U937 cells, Western blot, EMSA, siRNA knockdown, mRNA quantification (qRT-PCR), patient sample analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (conditional expression, siRNA rescue, EMSA, patient samples) in a single study establishing a novel translational mechanism\",\n      \"pmids\": [\"15855281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cbfb enhances osteogenic differentiation of mesenchymal stem cells by stabilizing Cbfa-1 (RUNX2) through suppression of ubiquitination-mediated proteasomal degradation; Cbfb alone does not trigger osteogenesis.\",\n      \"method\": \"Recombinant adenovirus overexpression of Cbfb and Cbfa-1 in mouse C3H10T1/2 cells and human BMSCs, Western blot, ubiquitination assay, alkaline phosphatase assay\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ubiquitination assay combined with protein stability experiments; single lab with two orthogonal methods\",\n      \"pmids\": [\"17379770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CBFB-MYH11 causes Cbfb/Runx1 repression-independent hematopoietic defects, including sustained expression of Gata2, Il1rl1, and Csf2rb in primitive hematopoiesis and accumulation of abnormal Csf2rb-expressing progenitors — a phenotype not found in Cbfb or Runx1 knockout mice — demonstrating that CBFβ-SMMHC has leukemogenic activities independent of dominant RUNX1 repression.\",\n      \"method\": \"Cbfb-MYH11 knock-in mouse model, comparison with Cbfb and Runx1 knockout mice, flow cytometry, gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis using multiple knockout backgrounds with specific phenotypic readouts; replicated across primitive and definitive hematopoiesis\",\n      \"pmids\": [\"20007544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GATA-1 transcriptionally represses Cbfb expression by co-occupying PU.1 motif sequences near the Cbfb locus; conditional activation of PU.1 or knockdown of GATA-1 leads to derepression of Cbfb associated with increased histone H3K9 acetylation.\",\n      \"method\": \"Conditional PU.1-ER activation in MEL cells, siRNA knockdown of GATA-1, ChIP, reporter assays, gene expression arrays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus siRNA rescue in a defined cell model; single lab, multiple methods\",\n      \"pmids\": [\"19825991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CBFβ-SMMHC localizes to RUNX1-occupied promoters genome-wide, where it interacts with TAL1, FLI1, TBP-associated factors (TAFs), ERG, GATA2, PU.1, EP300, and HDAC1; the majority of CBFβ-SMMHC target genes (including ID1, LMO1, JAG1) are actively transcribed and are repressed upon fusion protein knockdown, indicating CBFβ-SMMHC maintains expression of stem cell self-renewal genes.\",\n      \"method\": \"Genome-wide ChIP-seq, quantitative interaction proteomics (mass spectrometry), transcriptional analysis with shRNA knockdown of CBFB-MYH11\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide binding analysis combined with quantitative proteomics interactome and transcriptional perturbation; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"24002588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cbfb stabilizes all three Runx family proteins (Runx1, Runx2, Runx3) in chondrocytes and osteoblasts; conditional deletion of Cbfb in mesenchymal cells reduces Runx protein levels and impairs chondrocyte differentiation/proliferation and osteoblast differentiation; Runx2 protein stability is less dependent on Cbfb in calvariae than in cartilaginous limb skeletons.\",\n      \"method\": \"Conditional Cbfb knockout (Dermo1-Cre), Western blot for Runx protein levels, protein stability assay, reporter assays for Ihh/Col10a1/Bglap2 promoters, in vitro differentiation\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with multiple tissue-specific phenotypes, protein stability assay, reporter assays, and in vitro differentiation experiments; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"25262822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Runx1 activity is critical for Cbfb-MYH11-induced hematopoietic defects and leukemogenesis; loss of Runx1 (homozygous null or dominant-negative allele) rescues differentiation defects induced by Cbfb-MYH11 during primitive hematopoiesis and significantly reduces proliferation/differentiation defects in definitive hematopoiesis; Cbfb-MYH11-induced leukemia has longer latency in Runx1-deficient mice.\",\n      \"method\": \"Genetic epistasis: Cbfb-MYH11 knock-in combined with Runx1 null and dominant-negative alleles; mouse leukemia latency analysis, flow cytometry\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous genetic epistasis with multiple Runx1 alleles and defined hematopoietic and leukemia latency phenotypes; strong mechanistic evidence for pathway placement\",\n      \"pmids\": [\"25742748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CHD7 interacts with CBFβ-SMMHC through RUNX1 and enhances transcriptional activity of RUNX1 and CBFβ-SMMHC on target genes (e.g., Csf1r); Chd7 deficiency delays Cbfb-MYH11-induced leukemia by reducing LK progenitor proliferation and altering RUNX1 target gene expression.\",\n      \"method\": \"Co-immunoprecipitation (CHD7–CBFβ-SMMHC–RUNX1 interaction), conditional Chd7 knockout in Cbfb-MYH11 knock-in mice, in vitro transcription reporter assay, BrdU incorporation, RNA-seq, leukemia latency analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP interaction plus genetic epistasis with conditional knockout, reporter assay, and RNA-seq; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"29018080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"p53 induced by RUNX1 depletion directly binds to the CBFB promoter and stimulates CBFB transcription and translation; increased CBFB in turn acts as a platform for RUNX1 stabilization, creating a compensatory RUNX1-p53-CBFB feedback loop that confers resistance to chemotherapy in AML cells.\",\n      \"method\": \"RUNX1 siRNA knockdown, chromatin immunoprecipitation (p53 binding to CBFB promoter), reporter assay, Western blot for protein levels, AML patient sample analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus knockdown experiments establishing direct p53–CBFB promoter interaction; single lab, multiple methods\",\n      \"pmids\": [\"29192243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CBFB binds to hundreds of mRNAs via hnRNPK in the cytoplasm and enhances their translation through eIF4B; among the translationally regulated targets is RUNX1 mRNA itself. Nuclear CBFB/RUNX1 complex transcriptionally represses the NOTCH signaling pathway in breast cancer.\",\n      \"method\": \"RNA immunoprecipitation followed by deep sequencing (RIP-seq), co-immunoprecipitation (CBFB–hnRNPK, CBFB–eIF4B), polysome profiling, reporter assay, CBFB knockdown/rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — RIP-seq, co-IP, polysome profiling, and reporter assays collectively defining a noncanonical translation regulatory mechanism with multiple orthogonal methods in a single study\",\n      \"pmids\": [\"31061501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cbfb is an essential cofactor of Runx1 in anterior palatogenesis; Cbfb mutant mice exhibit failed epithelial disintegration at the anterior palate, disrupted TGFB3 expression, and impaired Stat3 phosphorylation; folic acid rescues anterior cleft palate by restoring Stat3 phosphorylation and Tgfb3 expression, placing Cbfb in a Runx1/Cbfb–Stat3–Tgfb3 signaling axis.\",\n      \"method\": \"Cbfb conditional knockout mouse, in vitro palatal fusion rescue with TGFB3 protein, folic acid treatment, immunostaining for phospho-Stat3 and TGFB3\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with defined phenotype, pathway rescue by TGFB3 and folic acid, phospho-signaling analysis; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"31171577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CBFB cooperates with p53 to maintain TAp73 expression; loss of either CBFB or p53 leads to TAp73 depletion; TAp73 re-expression abrogates the tumorigenic effect of CBFB deletion; TAp73 loss enhances tumorigenesis driven by NOTCH3 overexpression (a downstream event of CBFB loss).\",\n      \"method\": \"Integrated genomic analysis of CBFB/TP53 mutual exclusivity, CBFB and p53 knockdown, TAp73 re-expression rescue, xenograft tumor growth, immunohistochemistry\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown and rescue experiments with xenograft validation; single lab, multiple methods\",\n      \"pmids\": [\"33945523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The CBFB-MYH11 fusion protein sequesters RUNX1 in the cytoplasm, preventing RUNX1 from interacting with and recruiting DNMT3A to its target genes; CBFB-MYH11 expression phenocopies DNMT3A loss-of-function in producing DNA hypomethylation at RUNX1 target genes; CBFB-MYH11 mutations and DNMT3A mutations are mutually exclusive in AML.\",\n      \"method\": \"Co-immunoprecipitation (RUNX1–DNMT3A interaction), CBFB-MYH11 expression system, DNA methylation analysis, gene expression profiling, mutual exclusivity analysis in patient cohorts\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP defining direct RUNX1–DNMT3A interaction plus expression-system phenocopy and patient mutual exclusivity; single lab, multiple methods\",\n      \"pmids\": [\"34336831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CBFB localizes to mitochondria and functions in mitochondrial translation by enhancing the binding of mitochondrial mRNAs to TUFM (mitochondrial translation elongation factor); CBFB loss-of-function causes defective oxidative phosphorylation, Warburg effect, and autophagy/mitophagy addiction; this mitochondrial translation role cooperates with oncogenic PIK3CA mutations in breast cancer progression.\",\n      \"method\": \"Integrated omics (proteomics interactome of CBFB), mitochondrial fractionation, RIP demonstrating CBFB–mRNA–TUFM interaction, metabolic assays (OXPHOS, glycolysis), autophagy flux assays, mouse tumor models and PDX\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mitochondrial localization by fractionation, RIP demonstrating mRNA binding to TUFM, metabolic phenotyping, and in vivo PDX models; multiple orthogonal methods establishing a noncanonical CBFB function\",\n      \"pmids\": [\"36799863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Using proximity biotinylation (TurboID) in primary hematopoietic cells, CBFB::MYH11 interacting proteins are largely cytoplasmic, owing to interaction of the MYH11 domain with cytoplasmic myosin-related proteins; the CBFB domain of CBFB::MYH11 sequesters RUNX1 in cytoplasmic aggregates in primary human AML cells; paradoxically, CBFB::MYH11 expression is associated with increased RUNX1/2 transcription, suggesting a compensatory feedback mechanism.\",\n      \"method\": \"TurboID proximity biotinylation fused to oncofusion proteins in primary murine hematopoietic cells, mass spectrometry interactome, immunofluorescence/subcellular fractionation in primary human AML cells\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — unbiased proximity biotinylation proteomics plus orthogonal validation by immunofluorescence in primary human cells; rigorously controlled comparison with other AML oncofusions\",\n      \"pmids\": [\"38061017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A nonameric peptide derived from the CBFB-MYH11 fusion junction is naturally presented on HLA-B*40:01 on AML blasts and is immunogenic; high-avidity CD8+ T cell clones recognizing this neoepitope kill CBFB-MYH11+ AML cells in vitro and control AML in a patient-derived xenograft model in vivo.\",\n      \"method\": \"HLA peptide elution and mass spectrometry (neoantigen presentation), T cell cloning, cytotoxicity assays, TCR transduction, PDX mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mass spectrometry confirmation of natural antigen presentation, functional T cell killing assays, and in vivo PDX validation; multiple orthogonal methods\",\n      \"pmids\": [\"32831296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CBFB interacts with RUNX2 (co-immunoprecipitation confirmed), and miR-27b targets CBFB to inhibit hypertrophic chondrocyte differentiation of human BMSCs; CBFB knockdown by shRNA increases COL2/SOX9 expression and decreases COL10 expression.\",\n      \"method\": \"Co-immunoprecipitation (CBFB–RUNX2), luciferase reporter assay (miR-27b targeting CBFB 3'-UTR), shRNA knockdown of CBFB, RT-qPCR and Western blot, in vivo cartilage implant model\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirming CBFB–RUNX2 interaction, luciferase reporter, and shRNA phenotype with in vivo validation; single lab, multiple methods\",\n      \"pmids\": [\"32917285\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CBFB encodes the beta subunit of core-binding factor (CBF), which heterodimerizes with RUNX family proteins (RUNX1/2/3) via a conserved interaction surface to enhance their DNA binding and stabilize them against ubiquitin-mediated proteasomal degradation; together with CBF-A (NF-YB) and CBF-C (NF-YC) it also forms a trimeric CCAAT-binding complex with two additive transcriptional activation domains; the leukemia-associated CBFB-MYH11 fusion protein sequesters RUNX1 in cytoplasmic aggregates through its myosin tail, preventing RUNX1 from recruiting DNMT3A to target gene promoters and dominantly repressing CBF-dependent transcription, while also driving self-renewal gene expression; beyond its nuclear transcriptional role, CBFB localizes to mitochondria and promotes translation of mitochondrial mRNAs through TUFM, and in the cytoplasm it binds mRNAs via hnRNPK to enhance cap-dependent translation through eIF4B, collectively functioning as a tumor suppressor in breast and other cancers.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CBFB encodes the non-DNA-binding beta subunit of core-binding factor, which heterodimerizes with RUNX family transcription factors to enhance their DNA binding and protein stability, and serves as a master regulator across hematopoiesis, skeletal development, and craniofacial morphogenesis [#5, #8, #14]. Within the CCAAT-binding context, CBF-B associates with the CBF-A/CBF-C (NF-YB/NF-YC) histone-fold heterodimer—binding the hybrid surface they generate rather than either subunit alone—to form a heterotrimeric DNA-binding complex, and contributes one of two additive transcriptional activation domains [#0, #1, #2]. As a RUNX partner, CBFB binds RUNX1/2/3 to enhance their DNA binding and protect them from ubiquitin-mediated proteasomal degradation, an activity essential for Runx1-dependent hematopoiesis, Runx2-driven osteoblast and chondrocyte differentiation, and Runx1-dependent anterior palatogenesis through a Stat3–Tgfb3 axis [#5, #10, #14, #19, #25]. Beyond its nuclear role, CBFB functions in the cytoplasm by binding hundreds of mRNAs via hnRNPK to promote cap-dependent translation through eIF4B, and localizes to mitochondria where it enhances binding of mitochondrial mRNAs to the elongation factor TUFM to support oxidative phosphorylation, with loss of these activities cooperating with oncogenic PIK3CA in breast cancer—establishing CBFB as a tumor suppressor [#18, #22]. The leukemia-associated CBFB-MYH11 fusion generated by inv(16) acts as a dominant-negative oncoprotein that sequesters RUNX1 in cytoplasmic aggregates via its myosin tail, blocking RUNX1 from recruiting DNMT3A to target genes, while also independently driving expression of stem-cell self-renewal genes through occupancy of RUNX1 sites with cofactors including TAL1, FLI1, ERG, GATA2, PU.1, EP300, and CHD7 [#3, #13, #21, #23].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established the architecture of the CCAAT-binding CBF complex, showing CBF-B cannot bind DNA or individual subunits alone but joins a preformed CBF-A/CBF-C heterodimer.\",\n      \"evidence\": \"Recombinant protein reconstitution, EMSA, and immunoprecipitation with purified E. coli-expressed subunits\",\n      \"pmids\": [\"7878029\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the interaction domains structurally\", \"Relationship to RUNX-based CBF complexes not addressed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the molecular basis of CBF assembly and its transactivation capacity, mapping the histone-fold-dependent A/C heterodimer that creates a hybrid surface for CBF-B and locating two additive activation domains.\",\n      \"evidence\": \"Cross-linking, immunoprecipitation, CBF-C mutagenesis, yeast two-hybrid, and in vitro transcription reconstitution with deletion mutants\",\n      \"pmids\": [\"8754798\", \"8662945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro activation domains not validated in cellular promoter context\", \"No structural model of the trimeric surface\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated that the inv(16) CBFB-MYH11 fusion acts as a dominant-negative oncoprotein, with knock-in mice phenocopying the hematopoietic block of Cbfb or Runx1 null embryos.\",\n      \"evidence\": \"Knock-in mouse model, chimeric mouse analysis, embryo phenotyping; Western blot/EMSA/IF in patient nuclei\",\n      \"pmids\": [\"8929537\", \"8818654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of dominant inhibition not yet resolved\", \"Subcellular basis of RUNX1 inhibition undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Localized the dominant-negative mechanism to cytoplasmic sequestration of RUNX1 by CBFB-MYH11, with concomitant loss of transactivation and altered cell-cycle/apoptotic responses.\",\n      \"evidence\": \"Cell transfection and reporter assays (review summarizing prior experiments)\",\n      \"pmids\": [\"11561156\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level synthesis rather than a single primary dataset\", \"Structural determinant of sequestration in the MYH11 tail not yet mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined where in the hematopoietic hierarchy CBFB acts and where the fusion blocks differentiation, placing the defect at the stem/progenitor level.\",\n      \"evidence\": \"Cbfb-GFP knock-in reporter mouse with flow cytometry, compared to Cbfb-MYH11 knock-in embryos\",\n      \"pmids\": [\"12239155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address adult/definitive leukemogenesis directly\", \"Cell-intrinsic vs niche contributions not separated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extended CBFB function beyond blood to skeletal development by showing it is required for both Runx1 and Runx2 activity in osteoblast and chondrocyte differentiation.\",\n      \"evidence\": \"Cbfb knockout mouse rescue and genetic phenotyping of skeletal and hematopoietic tissues\",\n      \"pmids\": [\"12811622\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism (stabilization vs DNA binding) not yet distinguished\", \"Review-level summary\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed a non-transcriptional leukemogenic mechanism: CBFB-MYH11 suppresses CEBPA post-translationally by inducing calreticulin, an inhibitor of CEBPA translation.\",\n      \"evidence\": \"Conditional CBFB-SMMHC expression in U937 cells, Western blot, EMSA, calreticulin siRNA rescue, patient samples\",\n      \"pmids\": [\"15855281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which the fusion induces calreticulin unknown\", \"In vivo relevance to leukemia not established here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the biochemical basis of CBFB's role in osteogenesis as stabilization of RUNX2 against ubiquitin-mediated degradation.\",\n      \"evidence\": \"Adenoviral Cbfb/Cbfa-1 overexpression in C3H10T1/2 and human BMSCs, ubiquitination and protein stability assays\",\n      \"pmids\": [\"17379770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating RUNX2 degradation not identified\", \"Single overexpression system\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed CBFB-MYH11 has leukemogenic activities independent of dominant RUNX1 repression, producing unique gene-expression and progenitor phenotypes absent in knockout mice.\",\n      \"evidence\": \"Cbfb-MYH11 knock-in mice vs Cbfb and Runx1 knockouts, flow cytometry, gene expression analysis\",\n      \"pmids\": [\"20007544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular drivers of the repression-independent program not identified here\", \"Restricted to embryonic hematopoiesis readouts\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified upstream transcriptional control of CBFB, with GATA-1 repressing the locus by co-occupying PU.1 motifs.\",\n      \"evidence\": \"Conditional PU.1-ER activation and GATA-1 siRNA in MEL cells, ChIP, reporter assays, expression arrays\",\n      \"pmids\": [\"19825991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance in normal hematopoiesis unclear\", \"Single cell-line model\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established the genome-wide, gain-of-function transcriptional program of CBFB-MYH11, showing it maintains self-renewal gene expression at RUNX1 sites with a defined cofactor network.\",\n      \"evidence\": \"ChIP-seq, quantitative interaction proteomics, and shRNA knockdown transcriptional analysis\",\n      \"pmids\": [\"24002588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect cofactor recruitment not fully resolved\", \"Causal contribution of individual targets to leukemia untested here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Consolidated CBFB as a pan-RUNX stabilizer in skeletal tissue and showed RUNX1 activity is required for CBFB-MYH11 leukemogenesis via genetic epistasis.\",\n      \"evidence\": \"Conditional Cbfb knockout (Dermo1-Cre) with protein stability/reporter assays; Cbfb-MYH11 combined with Runx1 null and dominant-negative alleles, leukemia latency\",\n      \"pmids\": [\"25262822\", \"25742748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific differences in RUNX2 dependence not mechanistically explained\", \"Residual leukemia in Runx1-deficient background implies additional drivers\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified CHD7 as a cofactor enhancing RUNX1/CBFB-MYH11 transcription and a p53-RUNX1-CBFB feedback loop conferring chemoresistance.\",\n      \"evidence\": \"Co-IP, conditional Chd7 knockout in Cbfb-MYH11 mice, reporter/RNA-seq; RUNX1 siRNA, p53 ChIP on CBFB promoter, reporter, patient samples\",\n      \"pmids\": [\"29018080\", \"29192243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic exploitability of the feedback loop not tested\", \"Generality of CHD7 dependence across genotypes unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovered a cytoplasmic, non-canonical CBFB function in mRNA translation via hnRNPK/eIF4B and a tumor-suppressive nuclear role repressing NOTCH in breast cancer.\",\n      \"evidence\": \"RIP-seq, CBFB-hnRNPK and CBFB-eIF4B co-IP, polysome profiling, reporter assays, knockdown/rescue\",\n      \"pmids\": [\"31061501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CBFB partitions between nuclear and cytoplasmic roles unknown\", \"Selectivity for target mRNAs not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed CBFB in a Runx1-Stat3-Tgfb3 craniofacial signaling axis required for anterior palatogenesis, with folic acid rescue.\",\n      \"evidence\": \"Cbfb conditional knockout mouse, palatal fusion rescue with TGFB3, folic acid treatment, phospho-Stat3/TGFB3 immunostaining\",\n      \"pmids\": [\"31171577\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in the axis not mapped\", \"Mechanism of folic acid rescue unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated the CBFB-MYH11 fusion junction generates a presented, immunogenic neoantigen targetable by cytotoxic T cells, and that miR-27b regulates CBFB in chondrocyte differentiation.\",\n      \"evidence\": \"HLA peptide elution/MS, T cell cloning and cytotoxicity, TCR transduction, PDX; CBFB-RUNX2 co-IP, miR-27b luciferase reporter, shRNA knockdown, cartilage implant\",\n      \"pmids\": [\"32831296\", \"32917285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical efficacy of neoantigen-directed therapy untested\", \"HLA restriction limits applicability\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mechanistically connected the fusion's cytoplasmic RUNX1 sequestration to epigenetic dysregulation (blocked DNMT3A recruitment) and defined a CBFB-p53-TAp73 tumor-suppressive network.\",\n      \"evidence\": \"RUNX1-DNMT3A co-IP, CBFB-MYH11 expression, methylation/expression profiling, patient mutual exclusivity; CBFB/p53 knockdown, TAp73 rescue, xenografts\",\n      \"pmids\": [\"34336831\", \"33945523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect DNMT3A recruitment effects not fully separated\", \"Single-lab knockdown/rescue systems\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a mitochondrial translation role for CBFB via TUFM and used unbiased proximity proteomics to confirm the fusion's interactome is predominantly cytoplasmic, sequestering RUNX1 in aggregates.\",\n      \"evidence\": \"Proteomics interactome, mitochondrial fractionation, RIP (CBFB-mRNA-TUFM), metabolic/autophagy assays, PDX; TurboID proximity biotinylation in primary cells with IF validation\",\n      \"pmids\": [\"36799863\", \"38061017\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CBFB is imported to and retained in mitochondria unknown\", \"Paradoxical increased RUNX1/2 transcription with fusion not mechanistically resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CBFB is partitioned among its nuclear transcriptional, cytoplasmic translational, and mitochondrial roles—and how these are coordinately regulated in normal versus malignant cells—remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural or regulatory mechanism governing CBFB compartmentalization identified\", \"Relative contribution of each subcellular function to tumor suppression unquantified\", \"No structural model of CBFB-MYH11 cytoplasmic aggregates\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 10, 14]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [18, 22]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [18, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18, 23]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 13]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 14, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 13, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [18, 22]}\n    ],\n    \"complexes\": [\"core-binding factor (CBF/RUNX)\", \"CCAAT-binding factor (NF-Y) trimer\"],\n    \"partners\": [\"RUNX1\", \"RUNX2\", \"RUNX3\", \"hnRNPK\", \"eIF4B\", \"TUFM\", \"CHD7\", \"NFYC\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}